Viking Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Viking Therapeutics generated cash of -$73,376,000, which is less than the previous year. Cash used in financing activities reached the amount of $271,376,000 last year. Net change in cash is therefore $18,884,000.
Cash Flow
| 2014 | -1.59M | 0 | 2.16M |
|---|---|---|---|
| 2015 | -8.73M | -13.47M | 22.21M |
| 2016 | -11.07M | 3.02M | 10.34M |
| 2017 | -14.75M | -1.72M | 22.40M |
| 2018 | -18.75M | -265.72M | 300.27M |
| 2019 | -24.75M | 7.46M | 887K |
| 2020 | -21.77M | 41.56M | 950K |
| 2021 | -47.58M | 37.96M | 6.88M |
| 2022 | -48.39M | 54.75M | 4.16M |
| 2023 | -73.37M | -179.08M | 271.37M |
0VQA.L Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 36.63M | 26.37M | 29.11M | 8.37M | 24.77M | 8.98M | 3.07M | 768.55K | 755.85K | 179.61K |
Operating activities | ||||||||||
Net income | -85.89M | -68.86M | -54.99M | -39.49M | -25.77M | -22.06M | -20.57M | -14.73M | -23.40M | -21.88M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 292K | 291K | 296K | 277K | 260K | 477K | 1.37M | 1.94M | 1.02M | 0 |
Stock-based compensation expense | 16.75M | 8.67M | 6.1M | 5.81M | 3.74M | 0 | 1.45M | 1.79M | 2.60M | 6.25K |
| Deferred income tax benefit | 16.75M | 8.67M | 6.1M | 5.81M | 3.74M | 0 | 1.45M | 1.79M | 2.60M | 6.25K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 321K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -1.01M | 7.08M | -2.54M | 1.55M | 1.47M | -508K | 263.50K | 677.18K | 219.23K | 190.29K |
Cash generated by operating activities | -73.37M | -48.39M | -47.58M | -21.77M | -24.75M | -18.75M | -14.75M | -11.07M | -8.73M | -1.59M |
Investing activities | ||||||||||
Purchases Of Investments | -478.30M | -121.43M | -168.01M | -280.63M | -362.40M | -348.20M | -22.52M | -16.92M | -16.03M | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -179.08M | 54.75M | 37.96M | 41.56M | 7.46M | -265.72M | -1.72M | 3.02M | -13.47M | 0 |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 7.58M | 1.24M | 1.03M | 296.60M | 22.35M | 11.54M | 25.39M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -7.12M | -6.79M | -707 | -296 | -151 | -127 | 0 | -229 | -38 | -2 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | -3.83M | -77K | -94.86K | 0 | -2.5K |
Cash used in financing activities | 271.37M | 4.16M | 6.88M | 950K | 887K | 300.27M | 22.40M | 10.34M | 22.21M | 2.16M |
Net Change In Cash | 18.88M | 10.26M | -2.74M | 20.74M | -16.40M | 15.79M | 5.91M | 2.30M | 12.69K | 576.23K |
Cash at end of period | 55.51M | 36.63M | 26.37M | 29.11M | 8.37M | 24.77M | 8.98M | 3.07M | 768.55K | 755.85K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |